Dual Radiotherapy for Prostate Cancer

Clinical Trials

June 4, 2020 225Ac-J591 Phase I Data


“These Phase I trial results of the 225Ac-J591 antibody … are impressive, both from a response and safety standpoint. PSA declines and CTC responses were clearly evident.”

How Does the Dual Therapy Work?

Radiotherapy Monetization Datapoints

Other Radiotherapy Transactions

Scroll to Top


You are about to review presentations, reports and/or filings of AIkido Pharma Inc., that contain time-sensitive information. The information contained therein is only accurate as of the date thereof. AIkido Pharma Inc. will not be reviewing or updating the material that is contained in these items after the date thereof. The information contained therein may be updated, amended, supplemented or otherwise altered by subsequent presentations, reports and/or filings by AIkido Pharma Inc.